Pancreatic Cancer Research

ResearcherUniversity of CambridgeActive in the last 2 years

Shivan Sivakumar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5175-2697; OpenAlex author ID A5069801448, A5078697625, A5133312853, A5135314583. Sources: OpenAlex.

Their work

Papers
31 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
92
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 5 papers · 2024: 6 papers · 2025: 2 papers · 2026: 9 papers

Papers 31

  1. Linking Targeted Pancreatic Cancer Genes With Metabolic Disorders: A Cross-Species Translational Pathway. Co-author DOI 10.1002/cam4.71775↗
  2. In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment. Co-author DOI 10.1016/j.celrep.2025.116827↗
  3. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Co-author DOI 10.1016/j.hpb.2026.06.008↗
  4. Spatial Proteomics Uncovers Immune Cell Neighborhoods and Tumor-Immune Interfaces in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2026.101697↗
  5. Breaking the RAS Barrier in Pancreatic Cancer. Co-author DOI 10.1056/nejme2606948↗
  6. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  7. Intranetwork variation in neoadjuvant therapy delivery for borderline resectable and locally advanced pancreatic cancer: a UK multicentre cohort study. Co-author DOI 10.1308/rcsann.2026.0023↗
  8. Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review. Co-author DOI 10.3390/jcm15093225↗
  9. Coordinated immune architecture underlies durable survival in pancreatic cancer Co-author DOI 10.64898/2026.04.29.721612↗
  10. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Co-author DOI 10.1038/s41467-024-55424-2↗
  11. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  12. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.04.009↗
  13. Predicting the risk of pancreatic cancer in adults with new-onset diabetes: development and internal-external validation of a clinical risk prediction model. Co-author DOI 10.1038/s41416-024-02693-9↗
  14. The microbial composition of pancreatic ductal adenocarcinoma: a systematic review of 16S rRNA gene sequencing. Co-author DOI 10.1097/js9.0000000000001762↗
  15. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  16. Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma? Last author DOI 10.3389/fimmu.2024.1406250↗
  17. Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity. Co-author DOI 10.7554/elife.92672↗
  18. Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells. Last author DOI 10.1016/j.isci.2023.106324↗
  19. Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case-contr… Co-author DOI 10.1136/gutjnl-2021-326522↗
  20. Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15174265↗
  21. Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study. Co-author DOI 10.3390/ijms242316888↗
  22. Improving early diagnosis of pancreatic cancer in symptomatic patients First author DOI 10.3399/bjgp23x735585↗
  23. The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis. Co-author DOI 10.3390/jcm11092574↗
  24. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. First author DOI 10.1038/s41388-020-01578-4↗
  25. Predicting risk of pancreatic cancer in individuals with new-onset type-2 diabetes in primary care: protocol for the development and validation of a clinical p… Co-author DOI 10.1101/2021.12.22.21268161↗
  26. Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer. Co-author DOI 10.3390/cancers13081776↗
  27. Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. Co-author DOI 10.3390/jcm10030490↗
  28. Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer. Last author DOI 10.3390/cancers12123704↗
  29. Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes. Last author DOI 10.1002/ijc.32186↗
  30. Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypes Last author DOI 10.1101/198903↗
  31. Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis. Co-author DOI 10.1371/journal.pmed.1002223↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rachael J. M. Bashford-Rogers · 9 shared papers, 2021–2026 · strength 1.57
  2. Adam Enver Frampton · 8 shared papers, 2023–2026 · strength 1.41
  3. Lara Rosaline Heij · 9 shared papers, 2019–2026 · strength 1.39
  4. Nabeel Merali · 5 shared papers, 2023–2026 · strength 0.92
  5. Nicola E. Annels · 5 shared papers, 2023–2026 · strength 0.92
  6. Tarak Agrebi Moumni Chouari · 5 shared papers, 2023–2026 · strength 0.92
  7. Keith John Roberts · 4 shared papers, 2023–2026 · strength 0.85
  8. Michael Loran Dustin · 6 shared papers, 2017–2026 · strength 0.84
  9. Lewis A Hall · 3 shared papers, 2026 · strength 0.71
  10. Elisa Giovannetti · 4 shared papers, 2023–2026 · strength 0.68
  11. Georg J. Wiltberger · 4 shared papers, 2021–2025 · strength 0.56
  12. Ashley Kieran Clift · 3 shared papers, 2021–2024 · strength 0.54
  13. Carol A. C. Coupland · 3 shared papers, 2021–2024 · strength 0.54
  14. Julia Hippisley‐Cox · 3 shared papers, 2021–2024 · strength 0.54
  15. Pui San Tan · 3 shared papers, 2021–2024 · strength 0.54
  16. James Michael Halle-Smith · 2 shared papers, 2024–2026 · strength 0.47
  17. Ashwin Jainarayanan · 3 shared papers, 2021–2025 · strength 0.44
  18. Nikolaos A. Chatzizacharias · 2 shared papers, 2026 · strength 0.41
  19. Peter Lawrence Zaki Labib · 2 shared papers, 2026 · strength 0.41
  20. Sarah F. Powell-Brett · 2 shared papers, 2026 · strength 0.41
  21. Moath Alarabiyat · 2 shared papers, 2026 · strength 0.41
  22. Xiuxiang Tan · 3 shared papers, 2021–2025 · strength 0.40
  23. Shihong Wu · 2 shared papers, 2025–2026 · strength 0.37
  24. Dipanwita Nath · 1 shared paper, 2026 · strength 0.36
  25. Animesh Acharjee · 1 shared paper, 2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.